InVivo Therapeutics Appoints Christopher McNulty as Vice President, Business Development & Investor Relations
Business Wire - Tue Jul 01, 7:30AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the role of Christopher McNulty has been expanded to include investor relations and corporate communications. Mr. McNulty has been serving as Vice President, Business Development, and will continue to lead efforts in that area.
InVivo Therapeutics to Present at 4th International Neural Regeneration Symposium in China
Business Wire - Mon Jun 30, 7:30AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that InVivo's Director of Research Richard Layer, Ph.D., has been invited to speak at the Joint Symposium of the 4th International Neural Regeneration Symposium (INRS2014), 9th Asia Pacific Symposium on Neural Regeneration (APSNR2014), and 6th International Spinal Cord Injury Treatment and Trials Symposium (ISCITT2014), to be held September 6-8, 2014 in Nanjing, China (website: http://www.inrs-nrr.org/CN/model/index_en.shtml).
InVivo Therapeutics Announces Barrow Neurological Institute As Third Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Thu Jun 26, 7:30AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that a third clinical site, the Barrow Neurological Institute (BNI) in Phoenix, AZ, is now open for enrollment for patients with acute spinal cord injury (SCI). BNI at St. Joseph's Hospital and Medical Center is the largest dedicated neurosurgical center in the world and is a recognized leader in neurosurgical training, research, and patient care. More operative neurosurgical procedures take place at BNI than at any other institution in the United States. Nicholas Theodore, MD, Professor of Neurosurgery, Director of Neurosurgery Spine Program, and Director of Neurotrauma at BNI will be the study's Principal Investigator.
InVivo Therapeutics Announces New Responsibilities for Senior Management Team Members
Business Wire - Tue Jun 24, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the expansion of responsibilities for three members of its senior management team. The additional functional responsibilities, now at the senior management level, include Operations, Project Management, and Reimbursement Planning.
InVivo Therapeutics Announces Realignment of R&D Strategy
Business Wire - Mon Jun 23, 3:30PM CDT
As a result of an in-depth review of the company's research & development portfolio, InVivo Therapeutics has announced that the company is realigning resources behind its novel Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells program for spinal cord injury (SCI). Resources currently deployed towards InVivo's hydrogel drug delivery program will be eliminated. The hydrogel platform was at an early stage of preclinical development, and substantial financial and human resources would have been required to address technical and competitive challenges and to advance any drug delivery product to the partnering stage or into the clinic. The company indicated that one element of the hydrogel platform will be further explored, the potential of hydrogel for cell delivery, as part of an expanded biomaterials development program for the delivery of stem cells.
InVivo Therapeutics Appoints Steven McAllister as CFO
Business Wire - Thu Jun 19, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Steven McAllister as Chief Financial Officer, effective immediately. Mr. McAllister has been serving as InVivo's Interim CFO since December of 2013.
OncoSec Medical Inc. To Be Featured Presenter At 3rd Annual Marcum MicroCap Conference
ACCESSWIRE - Fri May 16, 7:58AM CDT
OncoSec Medical Incorporated (OTCQB: ONCS) saw its share volume slightly drop on May 15th with 2,589,613 shares exchanging hands, relatively lower than its three month daily average volume of 3,420,852 shares.
InVivo Therapeutics Announces Its Second Clinical Study Site for Neuro-Spinal Scaffold
Business Wire - Wed May 14, 3:06PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that a second clinical site in its clinical study, the Carolinas Medical Center in Charlotte, NC, is now open for enrollment for patients with acute spinal cord injury (SCI). Dom Coric, MD, of Carolina Neurosurgery & Spine Associates, Chief of Neurosurgery at Carolinas Medical Center, is a Co-Principal Investigator. William L. Bockenek, MD, Chief Medical Officer of Carolinas Rehabilitation, part of the Carolinas HealthCare System, and Chairman of the Department of Physical Medicine and Rehabilitation at Carolinas Medical Center, is also a Co-Principal Investigator.
OTC Daily Alert Stock Watch InVivo Therapeutics Holdings Corp (OTCQB: NVIV)
WorldStockWire - Mon Mar 24, 3:46AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
InVivo Therapeutics Reports 2013 Financial Results and Business Update
Business Wire - Mon Mar 17, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV), a life sciences company focused on the development and commercialization of novel drug delivery technologies as well as biopolymer devices for the treatment of spinal cord injuries and other nervous system conditions, today reported financial results for the year ended December 31, 2013.
InVivo Therapeutics Names Tamara L. Joseph as Its General Counsel and Chief Compliance Officer
Business Wire - Mon Mar 17, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Tamara L. Joseph as Senior Vice President, General Counsel and Chief Compliance Officer, effective March 24, 2014. Ms. Joseph comes to InVivo with extensive leadership experience in the biotechnology and pharmaceutical industries as a result of holding senior positions in the US and Europe over the past 16 years.
InVivo Therapeutics Names Thomas R. Ulich, MD as Its New Chief Scientific Officer
Business Wire - Mon Feb 24, 7:03AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced appointment of Thomas R. Ulich, MD as Chief Scientific Officer, effective February 24, 2014.
OTC Daily Alert Stock Watch - InVivo Therapeutics Holdings Corp
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
InVivo Therapeutics Holdings Corp sends amended protocol to FDA and six cllinical sites for approval
M2 - Mon Jan 06, 5:43AM CST
Biomaterials company InVivo Therapeutics Holdings Corp (OTC Markets:NVIV) reported on Friday the submission of the revised protocol and related study documents for a clinical study to test the safety of its investigational scaffold device for spinal cord repair to the US Food and Drug Administration.
InVivo Sends Amended Protocol to FDA and Six Clinical Sites
Business Wire - Fri Jan 03, 2:18PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has sent to the United States Food and Drug Administration the revised protocol and related study documents for a clinical study to test the safety of its investigational scaffold device for spinal cord repair. The revised protocol includes all changes that were conditions of approval by the FDA. On Monday, it will send the revised protocol and related study documents to six sites in the United States so that they can now begin their Institutional Review Board submissions and finalize clinical study contracts with InVivo.
Novel Health Initiative for Walgreen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 5:20PM CST
Walgreen undertakes a novel initiative to help in the implementation of the Affordable Care Act.
InVivo Announces Regulatory and Clinical Promotions
Business Wire - Fri Dec 27, 8:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the promotion of Lisa Crockett to Vice President, Regulatory and Kristin Neff to Vice President, Clinical Operations. These promotions are effective January 1, 2014.
InVivo Therapeutics to Move Forward with Its First Clinical Trial After Receiving FDA Conditional Approval
Business Wire - Thu Dec 26, 1:00PM CST
InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has received conditional approval from the Food and Drug Administration for proposed changes to the protocol and supporting documents for the safety trial of its first investigational product, a degradable polymer scaffold for spinal cord injury. InVivo submitted these proposed changes to the FDA on November 21, 2013 and will follow the FDA's approval conditions in their entirety in a submission to the FDA next week.
InVivo Therapeutics Holdings Corp elects Mark Perrin as CEO
M2 - Tue Dec 24, 7:14AM CST
Biomaterials company InVivo Therapeutics Holdings Corp (Other OTC:NVIV) reported on Monday the election of Mark D Perrin as its chief executive officer.
InVivo Names Mark Perrin as Its New Chief Executive Officer
Business Wire - Mon Dec 23, 3:30PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chief Executive Officer, effective January 6, 2014. Upon his appointment, Mr. Perrin will also become a member of the Board of Directors.